Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A0KFRJ1
Mon, 07.12.2020
CytoTools AG
Supervisory Board of CytoTools AG expresses trust in the Management Board after the Annual General Meeting
- More than 98 percent of the shareholders represented support the company's current strategy
- Shareholder group blocks large parts of the agenda with capital majority
- Objection of two shareholders against capital measure significantly belo [ … ]
Wed, 18.11.2020
CytoTools AG
CytoTools subsidiary completes establishment of German production and starts own production of DPOCL in Europe for the first time
- Production notified to the responsible regional council in accordance with the German Drug Law
- DermaTools is allowed to produce DPOCL for the European market
- In-house production is used directly to manufacture the [ … ]
Fri, 13.11.2020
CytoTools AG
Efficacy of DPOCL in COVID-19 confirmed by the Institute of Medical Virology at Frankfurt University Hospital
- Virus-killing effect of DPOCL on SARS-CoV-2 pathogens confirmed in test series
- New therapeutic approach to protect against infection by repeated daily inhalation
- Search for project partner for Fast Track approval and market launch sta [ … ]
Thu, 29.10.2020
CytoTools AG
CytoTools starts phase III study of DermaPro in Europe
- Study start in Germany in October and in up to seven other countries in the coming months
- High prospects of success after approval and market launch in India
- Sale of treasury shares generates extraordinary profit of EUR 0.33 million and creates additional financial leeway
Darmstadt, 29 O [ … ]
Thu, 15.10.2020
CytoTools AG
CytoTools positions itself for the admission of new investors by extending the agenda of the coming general meeting
- Postponement of the Annual General Meeting for comprehensive preparation of strategic steps
- Extension of the agenda by new authorized capital
- New strategic and institutional investors support the company's current course
Darmst [ … ]
Tue, 06.10.2020
CytoTools AG
CytoTools secures financing of the phase III study and appoints Chief Financial Officer
- Full financing of the Phase III study secured after registration of the capital increase
- Marc Herwick appointed Chief Financial Officer of CytoTools AG
Darmstadt, 6 October 2020 - The Management Board of CytoTools AG (ISIN DE000A0KFRJ1), a biotechnology hol [ … ]
Thu, 17.09.2020
CytoTools AG
CytoTools examines the effectiveness of its patented active substance DPOCL in COVID-19 infections
- Novel therapeutic approach for easy treatment of COVID-19 with DPOCL
- Proven active ingredient is delivered directly to the lungs as an inhalable aerosol
- Anti-viral effect of DPOCL demonstrated in first cellular test systems
Darmstadt, 17 Septem [ … ]
Thu, 03.09.2020
CytoTools AG
CytoTools partner Centaur Pharmaceuticals starts marketing the active substance DPOCL in India
- Scientific market launch program of DPOCL under the brand WOXheal(R) started
- Distribution via nationwide clinics chains and affiliated pharmacies
- Marketing start considered promising despite pandemic-related restrictions
Darmstadt, 3 September 2020 [ … ]
Wed, 26.08.2020
CytoTools AG
CytoTools introduces new strategic investor and restructures capital market communication- Pharma-CDMO Klocke Group participates as new strategic investor
- Milestone for financing of phase III of the approval process for DermaPro(R)
- Professionalization of investor relations for an improved capital market positioning through the signing of Interi [ … ]